Publikationer – Patrick Micke

Publikationer i DiVA

Publikationer i PubMed

Ett urval av våra publikationer:

  1. Uhlen M, Zhang C, Lee S, Sjöstedt E, Fagerberg L, Bidkhori G, Benfeitas R, Arif M, Liu Z, Edfors F, Sanli K, von Feilitzen K, Oksvold P, Lundberg E, Hober S, Nilsson P, Mattsson J, Schwenk JM, Brunnström H, Glimelius B, Sjöblom T, Edqvist PH, Djureinovic D, Micke P, Lindskog C, Mardinoglu A, Ponten F. A pathology atlas of the human cancer transcriptome. Science. 2017, 357(6352).
  2. Brunnström H, Johansson A, Westbom-Fremer S, Backman M, Djureinovic D, Patthey A, Isaksson-Mettävainio M, Gulyas M, Micke P. PD-L1 immunohistochemistry in clinical diagnostics of lung cancer: inter-pathologist variability is higher than assay variability. Mod Pathol. 2017 Jun 30.
  3. Grinberg M, Djureinovic D, Brunnström HR, Mattsson JS, Edlund K, Hengstler JG, La Fleur L, Ekman S, Koyi H, Branden E, Ståhle E, Jirström K, Tracy DK, Pontén F, Botling J, Rahnenführer J, Micke P. Reaching the limits of prognostication in non-small cell lung cancer: an optimized biomarker panel fails to outperform clinical parameters. Mod Pathol. 2017, 30(7):964-977.
  4. Djureinovic D, Hallström BM, Horie M, Mattsson JS, La Fleur L, Fagerberg L, Brunnström H, Lindskog C, Madjar K, Rahnenführer J, Ekman S, Ståhle E, Koyi H, Brandén E, Edlund K, Hengstler JG, Lambe M, Saito A, Botling J, Pontén F, Uhlén M, Micke P. Profiling cancer testis antigens in non-small-cell lung cancer. JCI Insight. 2016, 1(10):e86837.
  5. Micke P, Mattsson JS, Djureinovic D, Nodin B, Jirström K, Tran L, Jönsson P, Planck M, Botling J, Brunnström H. The Impact of the Fourth Edition of the WHO Classification of Lung Tumours on Histological Classification of Resected Pulmonary NSCCs. J Thorac Oncol. 2016, 11(6):862-72.
  6. Lindskog C, Edlund K, Mattsson JS, Micke P. Immunohistochemistry-based prognostic biomarkers in NSCLC: novel findings on the road to clinical use? Expert Rev Mol Diagn. 2015, 15(4):471-90.
  7. Lindskog C, Fagerberg L, Hallström B, Edlund K, Hellwig B, Rahnenführer J, Kampf C, Uhlén M, Pontén F, Micke P. The lung-specific proteome defined by integration of transcriptomics and antibody-based profiling. FASEB J. 2014, 28(12):5184-96.
  8. Micke P, Mattsson JS, Edlund K, Lohr M, Jirström K, Berglund A, Botling J, Rahnenfuehrer J, Marincevic M, Pontén F, Ekman S, Hengstler J, Wöll S, Sahin U, Türeci O. Aberrantly activated claudin 6 and 18.2 as potential therapy targets in non-small-cell lung cancer. Int J Cancer. 2014, 135(9):2206-14.
  9. Lohr M, Edlund K, Botling J, Hammad S, Hellwig B, Othman A, Berglund A, Lambe M, Holmberg L, Ekman S, Bergqvist M, Pontén F, Cadenas C, Marchan R, Hengstler JG, Rahnenführer J, Micke P. The prognostic relevance of tumour-infiltrating plasma cells and immunoglobulin kappa C indicates an important role of the humoral immune response in non-small cell lung cancer. Cancer Lett. 2013, 333(2):222-8.
  10. Botling J, Edlund K, Lohr M, Hellwig B, Holmberg L, Lambe M, Berglund A, Ekman S, Bergqvist M, Pontén F, König A, Fernandes O, Karlsson M, Helenius G, Karlsson C, Rahnenführer J, Hengstler JG, Micke P. Biomarker discovery in non-small cell lung cancer: integrating gene expression profiling, meta-analysis, and tissue microarray validation. Clin Cancer Res. 2013, (1):194-204.

Senast uppdaterad: 2022-04-10